Skip to main content
. Author manuscript; available in PMC: 2019 Jun 1.
Published in final edited form as: J Biomed Mater Res A. 2018 Feb 23;106(6):1753–1764. doi: 10.1002/jbm.a.36360

Figure 4.

Figure 4

Targeted binding of nanoparticles to cells and integrin molecules. A Binding of targeted (PLGA-PEG-AXT050) 100% NPs to MEC cells and MB-MDA-231 cells in suspension normalized to the binding of untargeted (PLGA-mPEG) 0% NPs. B Binding of targeted 100% NPs and non-targeted 0% NPs to integrin αvβ3, α5β1, and to human serum albumin as a negative control. Binding of targeted 100% NPs to integrin αvβ3 in the presence of a 100-fold excess of AXT050 peptide, an active fragment of AXT050 peptide, and scrambled AXT050 peptide.